Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Account Payables: 2015-2025

Historic Change in Account Payables for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$515,000.

  • Seres Therapeutics' Change in Account Payables fell 1455.26% to -$515,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year decrease of 71.97%. This contributed to the annual value of -$2.9 million for FY2024, which is 74.61% up from last year.
  • Seres Therapeutics' Change in Account Payables amounted to -$515,000 in Q3 2025, which was down 751.90% from $79,000 recorded in Q2 2025.
  • Seres Therapeutics' Change in Account Payables' 5-year high stood at $7.2 million during Q2 2022, with a 5-year trough of -$6.5 million in Q1 2022.
  • In the last 3 years, Seres Therapeutics' Change in Account Payables had a median value of -$515,000 in 2025 and averaged -$1.5 million.
  • Per our database at Business Quant, Seres Therapeutics' Change in Account Payables soared by 908.86% in 2022 and then slumped by 1,455.26% in 2025.
  • Over the past 5 years, Seres Therapeutics' Change in Account Payables (Quarterly) stood at $4.6 million in 2021, then increased by 19.04% to $5.5 million in 2022, then slumped by 192.41% to -$5.0 million in 2023, then grew by 17.40% to -$4.2 million in 2024, then plummeted by 1,455.26% to -$515,000 in 2025.
  • Its last three reported values are -$515,000 in Q3 2025, $79,000 for Q2 2025, and -$2.0 million during Q1 2025.